Department of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Cancer Res. 2023 Jun 2;83(11):1759-1761. doi: 10.1158/0008-5472.CAN-23-0624.
Metastasis is a key contributor to mortality in patients with cancer. While many regulators of metastasis have been identified, critical targets to prevent and inhibit metastatic tumor growth remain elusive. A recent study in this issue of Cancer Research by Deng and colleagues compared gene expression signatures between primary esophageal squamous cell carcinoma tumors and metastatic tumors and combined the analysis with genes induced in metastatic cancer cell lines, which identified anoctamin 1 (ANO1) as a key driver of metastasis. ANO1 caused cholesterol accumulation by inhibiting LXR signaling and decreased cholesterol hydroxylation by downregulating the expression of cholesterol hydroxylase CYP27A1. ANO1 also regulated tumor cell-fibroblast cross-talk that contributed to inflammatory cytokine signaling (IL1β) and metastasis. Through in silico analysis, the study identified a novel small-molecule inhibitor of ANO1 that decreased tumor burden at a metastatic site. These studies provide novel insights into the role of ANO1 in cellular cholesterol metabolism and associated signaling in mediating metastasis. See related article by Deng et al., p. 1851.
转移是导致癌症患者死亡的关键因素。虽然已经确定了许多转移的调节剂,但仍难以确定预防和抑制转移性肿瘤生长的关键靶标。在本期《癌症研究》杂志上,邓及其同事的一项研究比较了原发性食管鳞状细胞癌肿瘤和转移性肿瘤之间的基因表达特征,并将分析与转移性癌细胞系中诱导的基因相结合,确定了钙激活氯通道蛋白 1(ANO1)是转移的关键驱动因素。ANO1 通过抑制 LXR 信号通路导致胆固醇积累,并通过下调胆固醇羟化酶 CYP27A1 的表达来减少胆固醇羟化。ANO1 还调节肿瘤细胞-成纤维细胞的相互作用,促进炎性细胞因子信号(IL1β)和转移。通过计算机分析,该研究发现了一种ANO1 的新型小分子抑制剂,可减少转移部位的肿瘤负担。这些研究为 ANO1 在调节转移的细胞胆固醇代谢和相关信号中的作用提供了新的见解。见邓等人的相关文章,第 1851 页。